Johnson & Johnson will present more than 25 solid tumor abstracts at ESMO 2026, led by the first JNJ-6143 RIPTAC readout in prostate cancer, new RYBREVANT FASPRO head and neck data and ERLEADA PROTEUS findings.
ohnson & Johnson Q3 2026 Results: sales rose 5.9% to $25.4B, adjusted EPS hit $2.59 and 2026 guidance rose to $11.10 adjusted EPS at the midpoint.
Johnson & Johnson ICOTYDE (icotrokinra) reported two-year Phase 3 ICONIC-LEAD results at Fall Clinical Dermatology 2026. At Week 112, ≥72% of treated adults and adolescents with plaque psoriasis achieved PASI 90, with no new safety signals identified.
New MajesTEC-3 modeling from Johnson & Johnson finds that TECVAYLI plus DARZALEX FASPRO, used as early as second line, could give roughly 87% of relapsed/refractory multiple myeloma patients a mortality risk and life expectancy close to the general population, driven by a 90% drop in disease-progression risk versus standard of care.
Johnson & Johnson has reported pivotal Phase 3 findings for CAPLYTA (lumateperone) in bipolar mania, with the study showing significant and rapid improvement in manic symptoms.
Johnson & Johnson’s IMAAVY nipocalimab-aahu has received FDA approval as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), based on durable hemoglobin response data from the Phase 2/3 ENERGY study.
This Johnson & Johnson Q2 2026 Analysis breaks down JNJ’s second-quarter results $25.3 billion in worldwide sales, raised full-year guidance, and standout performance from its oncology and immunology drug portfolio.
Johnson & Johnson announced positive Phase 3 MonumenTAL-3 trial data demonstrating that a TALVEY-based bispecific combination significantly reduces the risk of progression or death in earlier-line relapsed or refractory multiple myeloma.
Johnson & Johnson has announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash to secure its novel Firelink™ degrader antibody conjugate platform.
Johnson & Johnson has shared late-breaking results from its Phase 2 JASMINE trial highlighting that nipocalimab achieves a sustained reduction in systemic lupus erythematosus (SLE) disease activity through 52 weeks.
